Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schwetz, V; Horvath, K; Kump, P; Lackner, C; Perren, A; Forrer, F; Pieber, TR; Treiber, G; Sourij, H; Mader, JK.
Successful Medical Treatment of Adult Nesidioblastosis With Pasireotide over 3 Years: A Case Report.
Medicine (Baltimore). 2016; 95(14):e3272-e3272
Doi: 10.1097/MD.0000000000003272
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Sourij Harald
- Theiler-Schwetz Verena
- Co-Autor*innen der Med Uni Graz
- Constantini-Kump Patrizia
- Horvath Karl
- Lackner Karoline
- Mader Julia
- Pieber Thomas
- Treiber Gerlies
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Nesidioblastosis is a rare cause of endogenous hyperinsulinemic hypoglycemia in adults. Diagnosis is often challenging and therapeutic options are scarce.In 2009, a 46-year-old female patient presented with recurrent severe hypoglycemia and immediate recovery after glucose ingestion. Although 72-h-fasting test was positive, various imaging technologies (sonography, computed tomography, somatostatin receptor scintigraphy, dopamine receptor positron emission tomography [DOPA-PET]) were negative. Endoscopic ultrasound revealed a lesion in the pancreatic corpus, whereas selective arterial calcium stimulation test, portal venous sampling and GLP-1-receptor scintigraphy were indicative of a lesion in the pancreatic tail, which was surgically removed. The histopathologic examination revealed beta cell hyperplasia and microadenomas expressing glucagon. After surgery, the patient was free of symptoms for 6 months, after which hypoglycemic episodes recurred. After unsuccessful treatment with corticosteroids and somatostatin analogs, treatment with pasireotide, a novel somatostatin analog with high affinity to somatostatin receptor 5 and a possible side effect of hyperglycemia, was initiated (0.6 mg BID). To date, our patient has been free of severe hypoglycemic episodes ever since. Yearly repeated imaging procedures have shown no abnormities over the last 3 years.We report for the first time that pasireotide was successfully used in the treatment of adult nesidioblastosis.
- Find related publications in this database (using NLM MeSH Indexing)
- Female -
- Humans -
- Middle Aged -
- Nesidioblastosis - drug therapy
- Remission Induction -
- Somatostatin - analogs & derivatives
- Somatostatin - therapeutic use
- Time Factors -